Aardvark Therapeutics is voluntarily pausing a global clinical trial testing whether its ARD-101 treatment candidate is superior to a placebo at easing hyperphagia, or insatiable hunger, in people with Prader-Willi syndrome (PWS). The company’s decision to pause the Phase 3 HERO trial (NCT06828861) was based on concerning…